The use of Zoely for menstrually-related migraine
The safety, tolerability and efficacy of Zoely (nomegestrol acetate/estradiol) for participants diagnosed with menstrually-related migraine
Monash University
30 participants
Nov 1, 2025
Interventional
Conditions
Summary
Migraine is a significant problem that predominantly affects young women. Hormonal changes associated with menstruation can be a trigger for migraine flares. We are investigating the use of a combined estrogen/progesterone contraceptive pill to see whether it is safe, well-tolerated and effective in treating the symptoms of menstrually-related migraine.
Eligibility
Inclusion Criteria1
- Aged 18-40 years at time of enrolment, current diagnosis of MRM without aura (ICHD-3 criteria), no change in migraine treatment in the preceding 3 months prior to enrolment and for the duration of the study, and no contraindications to hormonal therapy.
Exclusion Criteria1
- Aged over 40 years, migraine with aura, history of ischemic cerebral infarct/ stroke, history of thrombosis or blood clots, known disorder affecting blood clotting, history of breast, uterine or ovarian cancer, undiagnosed vaginal bleeding, liver disease, opioid medication overuse, pregnancy or plans to become pregnant during study period, or currently breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Zoely oral contraceptive pill (estradiol 2.5mg/ nomegestrol acetate 1.5mg) daily for 12 weeks. Adherence will be monitored through monthly telephone calls by investigators to each participant.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12625000644460